GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of Sweden: state board, and what it actually costs here — 15 comments in the full submission. View in context.
77
c/compounding·submitted 6 months ago by u/elise_ramos

Sweden: state board, and what it actually costs here

Regulatorybranch of 9 comments

Sweden: state board, and what it actually costs here, and I am aware this is a minority view on this board. Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot. Asked for the beyond-use date basis and got a real answer with a stability reference…

Read the full submission and all 15 comments →

This branch

9 comments, started 6 months ago
u/julia_erdogan6 points·6 months ago

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

replysharereportpermalink
u/rekha_mwangi5 points·6 months ago

Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.

replysharereportpermalink
[deleted]2 points·6 months ago

[deleted]

replysharereportpermalink
u/elise_ramos2 points·6 months ago

the shortage list is the whole legal hinge and people skip it

replysharereportpermalink
u/formulary_fighterappeals2 points·6 months ago

the shortage list is the whole legal hinge and people skip it

This is the distinction the whole board runs on. Everything else follows from it.

replysharereportpermalink
u/solene_eriksen1 point·6 months ago

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

replysharereportpermalink
u/hugo_bergstrom1 point·6 months ago·edited

the API source is the question nobody asks and everybody should

replysharereportpermalink
u/sigrid_kaufmann1 point·6 months ago

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

replysharereportpermalink
u/amara_kuipers1 point·6 months ago·edited

a 503B has to register and report, so there is a paper trail to ask for

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.